45 results
8-K
EX-99.1
ABBV
Abbvie Inc
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
of opioid products. Income tax items include a benefit of $323 million related to tax law changes partially offset by certain other tax related items. Other
8-K
EX-99.2
ABBV
Abbvie Inc
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
Bipolar Disorder 21.1M Post-Traumatic Stress Disorder 17.3M Generalized Anxiety Disorder 5.6M Schizophrenia 8.0M Opioid Use Disorder 2.9M Autism Spectrum … Selectively Targeting the Receptor Subtype Related to Disease Physiology M4: Muscarinic acetylcholine receptor M4; KOR: Kappa opioid receptor; PDE4B
8-K
EX-99.1
ABBV
Abbvie Inc
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
asset to AbbVie’s existing symptomatic therapies for advanced PD. CVL-354, currently in Phase 1, is a potential best-in-class kappa opioid receptor
8-K
EX-99.1
irpnrrls7swo
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
ox33axjr 1k
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
i2j9vm yzatdywlfb
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am
8-K
EX-99.1
djw787ci4
29 Jul 22
AbbVie Reports Second-Quarter 2022 Financial Results
7:49am
PX14A6G
g1prbfc2nhr7
4 Apr 22
Letter to shareholders
8:36am